www.cremieux.xyz/p/we-should-live-forever
1 correction found
Just in the past few years, we've gotten to witness the rise of GLP-1s, the advent of PCSK9 inhibitors
PCSK9 inhibitors are not a development from only the past few years. The first FDA-approved PCSK9 inhibitor, Praluent (alirocumab), was approved on July 24, 2015.
Full reasoning
This sentence groups PCSK9 inhibitors among developments that arrived "just in the past few years," but PCSK9 inhibitors entered clinical practice much earlier.
FDA materials state that Praluent (alirocumab) was first approved in the U.S. on July 24, 2015. A peer-reviewed review article in American Health & Drug Benefits likewise states that the first PCSK9 inhibitor was approved in July 2015 and that the FDA approved the first PCSK9 inhibitors in 2015.
Because this article was published on May 30, 2026, describing the advent of PCSK9 inhibitors as something from "just in the past few years" is inaccurate: their clinical advent dates back about 11 years, not a recent few-year window.
2 sources
- Clinical Review-Alirocumab | FDA
Praluent (alirocumab) was first approved in the U.S. on July 24, 2015, for use as an adjunct to diet and maximally tolerated statin therapy...
- The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice
The first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor was approved in July 2015 by the US Food and Drug Administration... The FDA approved the first PCSK9 inhibitors in 2015.